News | Radiation Therapy | June 03, 2016

Elekta’s Leksell Gamma Knife Icon Cleared for Use in Japan and United States

Patients and clinics to benefit from next-generation stereotactic radiosurgery system

Elekta, Leksell Gamma Knife Icon, Japan, United States, U.S. approval, radiosurgery system

June 3, 2016 — Elekta announced that its Leksell Gamma Knife Icon radiosurgery system has been cleared for clinical use by both the Japanese Ministry of Health, Labour and Welfare and the Nuclear Regulatory Commission in the United States.

Icon offers physicians increased flexibility for treatment of certain brain tumors, vascular malformations and functional disorders by allowing either frame-based or frameless methods to immobilize the patient’s head, while ensuring the highest level of precision. This allows patients with larger brain tumors and lesions close to critical brain structures to be treated with Gamma Knife accuracy and confidence.

Leksell Gamma Knife Icon received 510(k) approval from the U.S. Food and Drug Administration (FDA) in August 2015 and CE marking in June 2015. It has also been cleared by the MFDS for clinical use in The Republic of Korea.

The total number of cancer patients in Japan is estimated at about 980,000 a year, approximately 100,000 (10 percent) of whom will develop metastatic brain tumors. Only about 10,000 of these patients receive Gamma Knife treatment each year. Now, with Leksell Gamma Knife Icon, the number of patients who can receive stereotactic radiosurgery to the affected area would increase considerably.

Unique to Icon is the integrated stereotactic cone-beam CT (CBCT) imaging technology that can check the patient’s position against the treatment plan and automatically recalculate the plan to correct for movement, thus ensuring the highest precision. During treatment, Icon’s novel HD motion management system manages patient movement by using infrared marker tracking to monitor cranial position.

For more information: www.elekta.com

Related Content

Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Videos | Treatment Planning | August 28, 2018
A discussion with...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...
Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Overlay Init